Caris Life Sciences Announces New Study Demonstrating the Power and Clinical Utility of its Caris Assure® Blood-Based Assay for Multi-Cancer Early Detection, Minimal Residual Disease and Therapy Selec
IRVING, Texas, July 8, 2025 /PRNewswire/ — Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced a landmark study published in Scientific Reports, a Nature journal, demonstrating the accuracy and clinical utility of the Caris Assure® blood-based biopsy assay across the cancer continuum.
The Caris Assure® platform is a breakthrough single assay that combines comprehensive, highly sophisticated molecular profiling of all 23,000+ genes across DNA and RNA in plasma, setting a new blood-based testing standard and revolutionizing management of the cancer care journey. Additionally, Caris sequences DNA in the 'buffy coat,' the layer of centrifuged blood between the red blood cells and plasma, which contains white blood cells and platelets. Caris Assure combines Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) with advanced machine learning on a single platform. Caris Assure® is currently used for therapy selection and is capable of enabling accurate early detection and highly sensitive disease monitoring.
'We designed Caris Assure® to be more than a liquid biopsy test. This assay takes advantage of advanced sequencing and computing technology to capture genetic information available from the whole exome and whole transcriptome from the tumor material circulating in the blood and DNA from the patient's white blood cells,' said David Spetzler, MS, PhD, MBA, President of Caris. 'This enables us to provide a very comprehensive individualized picture of a patient's specific disease state. This is the first time so much molecular information has been available from a single blood test, allowing for increased accuracy and additional insights to inform physicians in helping to make cancer care decisions.'
The Caris Assure® liquid biopsy platform, powered by the Assure Blood-based Cancer Detection AI (ABCDai), was trained on over 376,000 whole exome and whole transcriptome tissue profiles and over 7,000 matched blood and tissue samples. In addition to therapy selection, the study validates the performance of Caris Assure® in:
Multi-Cancer Early Detection (MCED): Achieved sensitivities of 83.1% to 95.7% across cancer stages I–IV at 99.6% specificity.
Diagnostic Pathway Predictor: Accurately identified the diagnostic pathway for MCED-positive cancers using the ABCDai-GPS model.
MRD and Recurrence Monitoring: Demonstrated significant predictive power for recurrence, with hazard ratios of 33.4 (p < 0.005) for MRD and 4.39 (p = 0.008) for therapeutic monitoring.
Caris Assure® does not require a prior tissue biopsy. Instead, its AI model identifies tumor-derived signals based on patterns learned from hundreds of thousands of tumors. This enables a tissue-agnostic, highly sensitive approach to cancer detection and monitoring.
While Caris Assure® is currently commercially available for therapy selection in advanced cancers, this study lays the groundwork for expanding into early detection, MRD and therapeutic monitoring. Caris is actively pursuing reimbursement and regulatory pathways to bring these applications to market.
'This is more than a validation study; it is a blueprint for the future of cancer diagnostics,' added Spetzler. 'Our goal is to create a seamless ecosystem where patients and clinicians can rely on one platform throughout the entire cancer journey.'
About Caris Life Sciences Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.
The Scientific Report study is available on CarisLifeSciences.com.
Forward Looking Statements:This press release contains forward-looking statements, within the meaning of the federal securities laws, about Caris Life Sciences and its business. Statements about the performance and accuracy of Caris Assure discussed in this press release are based on testing and analysis to date, as reflected in the publication discussed, and future results and performance may differ materially from these findings. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases forward-looking statements can be identified by words such as 'may,' 'will,' 'should,' 'would,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'potential,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or similar expressions.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision oncology industry; future financial performance, results of operations or other operational results or metrics; development, validation and timing of future solutions; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; our compliance with laws and regulations; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' and elsewhere in the prospectus for our initial public offering filed with the Securities and Exchange Commission on June 20, 2025, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.
Caris Life Sciences Media: Corporate CommunicationsCorpComm@CarisLS.com214.294.5606
Investor Relations:Narendra ChokshiSenior Vice President, Corporate Developmentnchokshi@carisls.com917.689.3511
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
4 hours ago
- Malaysian Reserve
Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
CRANFORD, N.J. , July 8, 2025 /PRNewswire/ — Citius Pharmaceuticals, Inc. ('Citius Pharma' or the 'Company') (Nasdaq: CTXR) today announced that it has received formal notification from The Nasdaq Stock Market LLC ('Nasdaq') indicating that for 10 consecutive trading days, from June 20, 2025 to July 3, 2025, the closing bid price of the Company's common stock was at $1.00 per share or greater, and accordingly, the Company regained compliance with Nasdaq Listing Rule 5550(a)(2). The previously scheduled Nasdaq Hearing Panel has been cancelled. Nasdaq informed the Company that Citius Pharma's securities will continue to be listed and traded on the Nasdaq Stock Market. 'We are pleased to have regained compliance with Nasdaq's minimum bid price requirement,' said Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals. 'This reflects our continued focus on bringing critical care products to patients and creating long-term value for our shareholders.' About Citius Pharmaceuticals, Inc. Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Citius Pharmaceuticals owns 92% of Citius Oncology. For more information, please visit Forward-Looking Statements This press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma or Citius Oncology. You can identify these statements by the fact that they use words such as 'will,' 'anticipate,' 'estimate,' 'expect,' 'plan,' 'should,' and 'may' and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma and Citius Oncology, are: our ability to maintain compliance with Nasdaq's continued listing standards; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; our ability to use the latest technology to support our commercialization efforts; our need for substantial additional funds; our ability to successfully implement and maintain distribution agreements with current or other future distribution partners; potential disruptions or performance issues involving third-party logistics providers; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our SEC filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission ('SEC') filings which are available on the SEC's website at Investor Contact:Ilanit AllenVP, Corporate Communications & Investor RelationsCitius Pharmaceuticals, ext. 113 Media Contact:Greg SalsburgSTiR-communicationsGreg@ ext. 113
Malaysian Reserve
4 hours ago
- Malaysian Reserve
$2.35 Billion by 2030: Why In Situ Hybridization Is Revolutionizing Molecular Diagnostics
DELRAY BEACH, Fla. , July 8, 2025 /PRNewswire/ — What's driving the shift to spatially resolved molecular analysis? The global in situ hybridization market, valued at USD 1.64 billion in 2025, is projected to reach USD 2.35 billion by 2030, growing at a CAGR of 7.4%. This growth is driven by the expanding role of ISH in precision medicine, laboratory-developed tests (LDTs), and spatial transcriptomics. Technological innovations—including multiplex ISH, high-sensitivity probes, and automation—are enabling more accurate, efficient, and spatially resolved gene expression analysis in both clinical and research settings. From oncology to neuroscience, ISH is paving the way for advanced diagnostics and next-generation therapeutic strategies. Download PDF Brochure: Why is ISH becoming a molecular game-changer? In Situ Hybridization methods such as FISH and RNA-ISH are increasingly used to detect patient-specific genetic markers at the single-cell level. These techniques offer greater specificity and spatial resolution than conventional assays. For instance, Molecular Instruments' HCR Pro RNA-ISH LDT (Feb 2025) now enables differentiation between psoriasis and atopic dermatitis based on biopsy-derived immunologic markers—transforming diagnostics for millions with chronic skin conditions. Key players like Precision for Medicine, Scantox, and Plus Therapeutics are leveraging ISH to support oncology, gene therapy, and neurodegenerative disease research, further embedding these tools in drug development pipelines and personalized treatment planning. What challenges does ISH solve? ISH technologies address a number of persistent issues in molecular and histopathological diagnostics: Enables precise spatial mapping of gene expression across accuracy in difficult diagnoses where IHC or sequencing alone falls shortSupports multi-target detection for robust biomarker discovery and translational research through integration of transcriptomic and proteomic analyses. For example, Roche's FDA-cleared VENTANA Kappa and Lambda Dual ISH mRNA assay (Jan 2025) enhances lymphoma subtype detection, representing a breakthrough in ISH-based molecular diagnostics. Where is adoption accelerating the fastest? While North America leads with the largest market share due to established infrastructure and funding, rapid growth is forecasted in the Asia Pacific, driven by rising cancer incidence, government funding, and diagnostic modernization. Key momentum drivers include: China, India, and Japan investing heavily in molecular pathology labs expanding ISH capabilities for cancer and infectious disease academic and CRO adoption of automated, scalable ISH platforms. Request Sample Pages : Who are the key leaders—and how are they gaining ground? The ISH market is consolidated, with 5 major players holding 60–65% of global market share: F. Hoffmann-La Roche Ltd (Switzerland): Leading in automated ISH diagnostics, including BenchMark ULTRA PLUS and FDA-cleared lymphoma probes. Danaher (US): Through Leica Biosystems, focuses on integrated automation and spatial biology (US): Dominant in ISH probes for oncology and cytogenetics under the VYSIS (US): RNAscope portfolio expansion to 70,000+ probes position it as a spatial transcriptomics Fisher Scientific (US): Offers a comprehensive suite of ISH instruments and consumables. Recent innovations include: Leica + Bio-Techne (Apr 2025): Automated RNAscope Multiomic LS for spatial + Molecular Instruments (Jan 2025): Launched HCR Pro RNA-ISH for high-sensitivity (Jan 2025): FDA-cleared B-cell ISH + Biocare (Mar 2025): NeoPATH Pro ISH system distributed in the US. What's the biggest challenge—and how do we overcome it? Despite promising advances, high costs and technical complexity remain barriers: Capital investment: ISH instruments like Ventana Benchmark Ultra cost ~$100, Multiplex probe kits and imaging services are costly, with per-slide fees reaching $113 or protocols: Require skilled personnel and careful costs: Advanced scanners such as Vectra can cost $200/hour to operate. Solutions must focus on: User-friendly automation platforms with streamlined optimization to reduce cost per initiatives to expand technical modular platforms for research and clinical users alike. What should diagnostics leaders be asking now? Not 'Is ISH useful?'—but rather: How can ISH improve our ability to detect spatial gene expression at single-cell resolution?Which multiplexing and automation technologies can scale with our diagnostics needs?Are our assays ready for regulatory validation and clinical deployment?How can we integrate transcriptomics and proteomics within one platform? Final Thought: In Spatial Precision, There Is Power. In Multiplexing, There Is Clarity. As genomics shifts toward spatial, multiplexed, and clinically actionable diagnostics, in situ hybridization is evolving from a research tool into a cornerstone of precision healthcare. It's not just about detection anymore—it's about localization, integration, and transformation of diagnostics. In the future of molecular medicine, personalization begins with precision—and ISH is leading the charge. Key Market Players: F. Hoffmann-La Roche Ltd (Switzerland), Danaher (US), Abbott (US), Bio-Techne (US), Thermo Fisher Scientific (US), Bioview (Israel), Biocare Medical (US), Agilent Technologies (US), QIAGEN (Germany), CytoTest Inc. (US), Genemed Biotechnologies (US), ZytoVision GmbH (Germany), Abnova (Taiwan) For more information, Inquire Now! Related Reports: Companion Diagnostics Market Immunohistochemistry Market Tissue Diagnostics Market Immuno Oncology Assays Market Cancer Diagnostics Market Get access to the latest updates on Top Companies in In Situ Hybridization and In Situ Hybridization Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo; View original content:
Malaysian Reserve
9 hours ago
- Malaysian Reserve
Caris Life Sciences Announces New Study Demonstrating the Power and Clinical Utility of its Caris Assure® Blood-Based Assay for Multi-Cancer Early Detection, Minimal Residual Disease and Therapy Selec
Scientific Reports study validates the first multifunctional, AI-enabled blood-based assay to offer diagnostic, prognostic and predictive utility in a single assay. IRVING, Texas, July 8, 2025 /PRNewswire/ — Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced a landmark study published in Scientific Reports, a Nature journal, demonstrating the accuracy and clinical utility of the Caris Assure® blood-based biopsy assay across the cancer continuum. The Caris Assure® platform is a breakthrough single assay that combines comprehensive, highly sophisticated molecular profiling of all 23,000+ genes across DNA and RNA in plasma, setting a new blood-based testing standard and revolutionizing management of the cancer care journey. Additionally, Caris sequences DNA in the 'buffy coat,' the layer of centrifuged blood between the red blood cells and plasma, which contains white blood cells and platelets. Caris Assure combines Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) with advanced machine learning on a single platform. Caris Assure® is currently used for therapy selection and is capable of enabling accurate early detection and highly sensitive disease monitoring. 'We designed Caris Assure® to be more than a liquid biopsy test. This assay takes advantage of advanced sequencing and computing technology to capture genetic information available from the whole exome and whole transcriptome from the tumor material circulating in the blood and DNA from the patient's white blood cells,' said David Spetzler, MS, PhD, MBA, President of Caris. 'This enables us to provide a very comprehensive individualized picture of a patient's specific disease state. This is the first time so much molecular information has been available from a single blood test, allowing for increased accuracy and additional insights to inform physicians in helping to make cancer care decisions.' The Caris Assure® liquid biopsy platform, powered by the Assure Blood-based Cancer Detection AI (ABCDai), was trained on over 376,000 whole exome and whole transcriptome tissue profiles and over 7,000 matched blood and tissue samples. In addition to therapy selection, the study validates the performance of Caris Assure® in: Multi-Cancer Early Detection (MCED): Achieved sensitivities of 83.1% to 95.7% across cancer stages I–IV at 99.6% specificity. Diagnostic Pathway Predictor: Accurately identified the diagnostic pathway for MCED-positive cancers using the ABCDai-GPS model. MRD and Recurrence Monitoring: Demonstrated significant predictive power for recurrence, with hazard ratios of 33.4 (p < 0.005) for MRD and 4.39 (p = 0.008) for therapeutic monitoring. Caris Assure® does not require a prior tissue biopsy. Instead, its AI model identifies tumor-derived signals based on patterns learned from hundreds of thousands of tumors. This enables a tissue-agnostic, highly sensitive approach to cancer detection and monitoring. While Caris Assure® is currently commercially available for therapy selection in advanced cancers, this study lays the groundwork for expanding into early detection, MRD and therapeutic monitoring. Caris is actively pursuing reimbursement and regulatory pathways to bring these applications to market. 'This is more than a validation study; it is a blueprint for the future of cancer diagnostics,' added Spetzler. 'Our goal is to create a seamless ecosystem where patients and clinicians can rely on one platform throughout the entire cancer journey.' About Caris Life Sciences Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. Caris was founded with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. The Scientific Report study is available on Forward Looking Statements:This press release contains forward-looking statements, within the meaning of the federal securities laws, about Caris Life Sciences and its business. Statements about the performance and accuracy of Caris Assure discussed in this press release are based on testing and analysis to date, as reflected in the publication discussed, and future results and performance may differ materially from these findings. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases forward-looking statements can be identified by words such as 'may,' 'will,' 'should,' 'would,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'potential,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or similar expressions. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision oncology industry; future financial performance, results of operations or other operational results or metrics; development, validation and timing of future solutions; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; our compliance with laws and regulations; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' and elsewhere in the prospectus for our initial public offering filed with the Securities and Exchange Commission on June 20, 2025, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. Caris Life Sciences Media: Corporate CommunicationsCorpComm@ Investor Relations:Narendra ChokshiSenior Vice President, Corporate Developmentnchokshi@
